Alphabetic Index FY2027

D3A.023

Benign carcinoid tumor of the transverse colon

FY2027Chapter 2: Neoplasms/D3A Benign neuroendocrine tumors

BillableComplete code, valid to report
Care settingsHome Health Primary · MMTA - Infectious Disease, Neoplasms, and Blood-Forming DiseasesIPF Comorbidity · Oncology Treatment

D3A.023 (also written D3A023) is a billable ICD-10-CM diagnosis code for benign carcinoid tumor of the transverse colon. It is part of the FY2027 code set, effective October 1, 2026. It is one of the 22 codes in category D3A (Benign neuroendocrine tumors). The Alphabetic Index lists it under 1 entry. Its coding notes include a Use additional code instruction, a Code also instruction and 1 Excludes2 entry.

Use additional code

Add the listed code as a secondary code, if known.

Inherited from D3A Benign neuroendocrine tumors
  • code to identify any associated endocrine syndrome, such as:

Code also

Two codes may be needed to describe the condition. This note gives no sequencing order.

Inherited from D3A Benign neuroendocrine tumors
  • any associated multiple endocrine neoplasia [MEN] syndromes (E31.2-)

Excludes2

Not included here. Both codes may be reported if the patient has both conditions.

Inherited from D3A Benign neuroendocrine tumors
  • benign pancreatic islet cell tumors (D13.7)

Care settings

How CMS programs treat this code. These are CMS claim edits and list entries, not coverage or eligibility rules.

Home Health Primary

Accepted as the primary (principal) diagnosis on a home health claim. The Home Health Grouper assigns it to the MMTA - Infectious Disease, Neoplasms, and Blood-Forming Diseases clinical group.

Source: CMS Home Health Grouper Software v07.2.26, effective October 1, 2026

IPF Comorbidity

On the CMS IPF comorbidity list.

Comorbidity categoryFactor
Oncology Treatment1.44
It counts as a comorbidity when reported as a secondary diagnosis and actively treated during the stay. An IPF receives only one adjustment within a category and can receive adjustments in more than one category.

Source: CMS IPF PPS FY 2027 final rule (CMS-1847-F), Addendum B-3 (comorbidity codes with adjustment factor); effective for discharges on or after October 1, 2026

Notes

Also from chapter/block level (8 notes)
Inherited from Chapter 2 Neoplasms
  • Functional activity
  • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
  • Morphology [Histology]
  • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
  • Primary malignant neoplasms overlapping site boundaries
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
  • Malignant neoplasm of ectopic tissue
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

Alphabetic Index terms

Terms the official Alphabetic Index lists for this code. 1 entry